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Abstract: The selection or procurement of blood collection 
devices in healthcare facilities is often an underestimated 
issue. This is probably due to different factors including 
the lack of knowledge of policymakers, hospital admin-
istrators and even laboratory managers about the impor-
tance of preanalytical quality and phlebotomy process, as 
well as to the absence of reliable guidelines or recommen-
dations on how to precisely assess the quality of blood 
collection devices around the globe. With the awareness 
that a gap remains between manufacturers’ and local vali-
dation of blood collection devices, the Working Group for 
Preanalytical Phase (WG-PRE) of the European Federation 
of Clinical Chemistry and Laboratory Medicine (EFLM) 
has drafted a consensus document aimed to provide a set 
of essential requisites, technical criteria (e.g. presence of 
physical defects, malfunctioning, safety problems) and 
clinical issues for supporting laboratory professionals in 
organization blood collection tubes tenders and validat-
ing new devices before local routine implementation. The 
laboratory professionals should also make sure that the 
tenders accurately and strictly define the responsibili-
ties for validation experiments and the potential conse-
quences in the case the validation outcome shows that 
tubes due not fulfill the expectations.
Keywords: blood collection; blood tubes; errors; preana-
lytical variability; venipuncture.
Introduction
Preanalytical variability plays a crucial role in laboratory 
diagnostics [1]. Several lines of evidence, accumulated 
over the past decades, attest that most errors through-
out the testing process emerge from manually intensive 
activities related to collection and management of bio-
logical samples [2]. The use of high quality blood collec-
tion devices is an aspect of utmost importance in routine 
laboratory practice, wherein inappropriate or even differ-
ent sample containers may be a source of preanalytical 
bias, which can ultimately impact results of testing both 
in clinical and research settings [3]. It is also noteworthy 
that both the International Organization for Standardiza-
tion (ISO) 9001:2008 and the ISO 15189:2012 certification 
and accreditation procedures include standards encom-
passing all laboratory activities, including preanalytical 
procedures, which should be standardized and monitored 
according to evidence-based practices.
Despite accumulating evidence about pre analytical 
quality assurance, selection and procurement of blood 
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collection devices in healthcare facilities is often an 
underestimated issue. National, regional and local 
tenders are frequently plagued by policies, guided pri-
marily by the price rather than by quality of devices. This 
is probably due to different factors, including the lack of 
knowledge of policymakers, hospital administrators and 
even laboratory managers about the importance of pre-
analytical quality and the phlebotomy process, as well as 
to the absence of reliable guidelines or recommendations 
on how to precisely assess the quality of blood collection 
devices around the globe.
Validation studies are crucial activities for generat-
ing reliable evidence that a novel instrument, method, 
reagent or device is fit for purpose and satisfies the par-
ticular requirements for its specific intended use [4]. In 
2010, the Clinical and Laboratory Standards Institute 
(CLSI) released a specific GP-34A guideline, aiming to 
detail the procedures for validation and verification of 
tubes for venous or capillary blood specimen collec-
tion [5]. However, this document is mainly orientated 
towards validation of blood collection tubes from a 
 manufacturer’s perspective to ensure that design goals 
and performance claims are met. With the awareness 
that a gap remains between manufacturers validation 
and clinical laboratories implementation, the Working 
Group for Preanalytical Phase (WG-PRE) of the European 
Federation of Clinical Chemistry and Laboratory Medi-
cine (EFLM) has drafted the present consensus docu-
ment, which aims to provide a set of simple elements 
and criteria specifically for laboratory professionals, to 
verify whether the introduction of new blood collection 
tubes in clinical laboratories fulfills basic criteria of tech-
nical and clinical acceptability.
Operative definitions
In agreement with the CLSI guideline GP-34A [5], the 
“comparative tube” is defined as the blood collec-
tion tube currently used by the clinical laboratory, the 
“control tube” is defined as the blood collection tube that 
is to be introduced and replace the current. The “desir-
able quality specifications for bias” are conventionally 
derived from biological variation. The “validation” is 
finally defined according to the current ISO 9000:2005 
specifications [6], as “confirmation, through the provi-
sion of objective evidence that the main requirements 
for a specific intended use or application have been 
fulfilled”.
Essential requisite for purchasing 
blood collection devices
Blood collection systems are considered as integrated in 
vitro diagnostic (IVD) medical devices and are thereby 
regulated by a number of national and supranational 
bodies and organizations such as the European Com-
munity (EC) or the US Food and Drug Administration 
(FDA) [7]. A key characteristic, highlighted by virtually all 
regulatory documents, is that the whole blood collection 
device (i.e. safety needle, butterfly needle, holder and 
blood tube) must be regarded as an integrated system. 
Therefore, the combination of the different parts must 
be safe and should not impair the performance of the 
individual components [8]. Manufacturers are responsi-
ble for assuring the full compatibility between the com-
ponents of the system, to subside the risk of impairing 
the quality of testing and jeopardizing (both operator and 
patient) safety. Importantly, tenders allowing acquisition 
of devices from different manufacturers may end up with 
combinations that are not validated for clinical use. The 
manufacturers themselves also typically include specific 
claims in their product datasheets, stating that “devices 
(needles, single-use holders, safety devices) are designed 
to be used as a system of products, and the integration 
of other manufacturer’s products is solely the respon-
sibility of the user”. However, according to the EFLM 
WG-PRE, it is outside the role and duty of laboratory 
professionals to perform a thoughtful validation study 
to establish whether or not an integrated system is safe 
and does not impair the quality of testing. Therefore, the 
possibility of using separate parts of the blood collection 
system obtained or purchased from different manufactur-
ers is strongly discouraged by the EFLM WG-PRE except 
when the integration has been previously validated by 
the manufacturer(s) or by national or supranational 
 regulation bodies.
Apart from research and development, tube manufac-
turers should be able to also demonstrate usability studies 
of their products following study subject recruitment 
according to Good Clinical Practice/International Con-
ference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (GCP/IHC) 
guidelines and independent Ethical Committee requests. 
Demonstration of ease of use, sustained plasma quality, 
perceived value compared to the comparative devices 
and potential performance risk should be included. User 
(named sites) feedback on collection, transport (foot, 
pneumatic tube, courier, etc.), reception and analysis 
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results are especially valuable. The tubes/devices should 
also be analyzed by the manufacturer in different clinical 
settings, on major instrument platforms and investigated 
for potential test result bias and/or imprecision of ana-
lytes especially where this may be important for clinical 
decision making, including serum indices and analytes 
with known instability over time. The reasons for failures 
including missing and excluded data should be stated. 
For new suppliers evidence of factory capacity over time 
should also be supplied. The EFLM WG-PRE does however, 
also recommend that a laboratory performs a local valida-
tion of all new blood collection tubes (i.e. control tubes) 
estimating the potential bias and imprecision of test 
results compared to the previously used material (i.e. 
comparative tubes) to verify the manufactures claims. 
This approach has been proven by the constantly growing 
number of studies in all areas of diagnostic testing [9–12], 
including molecular biology [13, 14].
The costs attributable to using an appropriate 
number of tubes for a local validation (as described in 
the following parts of this article) should be charged 
to the manufacturers participating in the tender. More 
specifically, the details of the validation process should 
be included in the tender specification, with a specific 
request to the manufacturers to supplement the labora-
tory with a number of tubes and cost of reagents that is 
sufficient to complete each part of the validation. Con-
sideration should also be given to the process of sub-
mitting the validation to an Ethical committee and/or 
Institutional review board for approval (as for CLSI rec-
ommendations) [5]. Last but not least, the commission of 
a tender for purchasing blood collection devices should 
always include not less than one laboratory professional 
among the members (Table 1).
Validation of blood tubes
In the following sections of this article, the EFLM WG-PRE 
suggest a consensus protocol and some pertinent indica-
tors that may be used for the local validation, both tech-
nical and clinical, of new (i.e. “control”) blood collection 
tubes, to be compared with the current system in use by 
the same laboratory (i.e. “comparative” blood tubes).
Local technical validation of blood collection 
tubes
The local (user) technical validation of blood collec-
tion tubes should be intended to verify whether the 
Table 1: Essential requisites for purchasing blood collection devices.
1.  Components of the blood collection system in use (i.e. safety 
needle, butterfly needle, holder and blood tube) should be 
produced by the same manufacturer or else the combination/
integration of separate parts should be validated by accredited 
regulation organizations such as the European Community (EC) 
or the US Food and Drug Administration (FDA).
2.  Manufacturers should demonstrate performance studies of their 
products following study subject recruitment.
3.  Manufacturers should demonstrate ease of use, sustained 
plasma quality, perceived value compared to the comparative 
devices on the market and the risk associated with the use of 
their product.
4.  Failure rates per 10,000 tubes should be stated for each tube 
type. The reasons for failures, including missing and excluded 
data, should also be stated during usability studies.
5.  New suppliers should provide evidence of capacity to produce 
the product over longer period of time (at least 2 years).
6.  The cost for the appropriate number of tubes and reagents 
for local validation should be charged to the manufacturers 
participating in the tender.
7.  The validation study should be submitted for Ethical committee 
and/or Institutional review board approval.
8.  The committee for a tender for blood collection devices should 
always include not less than one laboratory professional.
manufacturer claims about structure, assembly, function-
ality and safety of the new (i.e. “control”) blood collection 
tubes are fulfilled, as verified by using local practices. 
Preferably, the sample size should include not  < 240 blood 
collections randomized to both the control (n = 120) and 
the comparative (n = 120) blood tubes, as recommended by 
the CLSI guidelines EP28-A3 to meet the minimum require-
ments for reliability and usefulness [5]. As an alternative, 
the collection of two paired tubes from the same patient 
with the two different systems may be advisable for a more 
stringent comparison, although not strictly necessary for 
this technical validation. Patients who are difficult to bleed 
should be excluded, as they may skew the data. For the 
technical validation, the EFLM WG-PRE supports recording 
the following information:
1. Tubes with physical defects of manufacturing (calcu-
late percentage)
2. Tubes with no vacuum or that fail to form a vacuum 
(calculate percentage)
3. Tubes not properly fitting into the blood collection 
device (calculate percentage)
4. Tubes under filling after blood collection (i.e. 10% 
lower than the nominal filling volume; calculate 
 percentage) [15]
5. Leaking from tube caps (calculate percentage)
6. External surface contamination with blood at the end 
of venipuncture (calculate percentage)
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Table 2: Acceptability criteria for technical validation of new blood collection tubes.
Item   Acceptable difference
Tubes with physical defects of manufacturing    < 1%
Tubes with no vacuum or that fail to form a vacuum    < 1%
Tubes not properly fitting into the blood collection device    < 1%
Tubes under filling    < 1%
Tubes leaking from the cap before and after centrifugation    < 1%
Blood contamination of collection device    < 1%
Hemolyzed specimens    < 1%a
Undue clotting  
 EDTA blood tubes    < 1%
 Sodium citrate blood tubes    < 1%
Tubes broken or spilling blood after centrifugation    < 1%
Inappropriate positioning of gel separator    < 1%
Serum blood tubes with incomplete clotting    < 1%
   
∗ − ∗      
number of comparative tubes number of control tubesDifference: 100 100.
120 120
 aWhen causes other than the blood tube (e.g. blood 
 collection device, phlebotomists, sample transportation or patient population) can be excluded.
7. Hemolyzed specimens, with significant hemolysis 
(e.g. 0.5 g/L) defined according to local practices (cal-
culate percentage)
8. Undue clotting in (a) EDTA and (b) sodium citrate 
blood tubes (calculate percentage of undue clotting in 
each type of blood tubes)
9. Tubes broken or spilling blood after manufacturer-
specific centrifugation (calculate percentage)
10. Inappropriate positioning of gel separator after manu-
facturer-specific centrifugation (calculate percentage)
11. Serum tubes with incomplete clotting after manufac-
turer-specific handling (i.e. time for clotting, centrifu-
gation conditions; calculate percentage)
For the calculation of maximum allowable deviation, the 
EFLM WG-PRE is in support of estimating the percentage 
of each indicator for 120 tubes of both the control and com-
parative blood tubes according to the formula reported in 
Table 2. When the difference between the comparative and 
control blood tubes is higher than the acceptability criteria 
consensually agreed by the EFLM WG-PRE for each of the 
selected indicators (i.e. 1%), then consideration that the 
comparative blood tubes have failed to pass the valida-
tion process should be raised. Importantly, the EC Direc-
tive 93/42/EEC appoints that any instrument, apparatus, 
appliance, material or other article, whether used alone or 
in combination that is intended by the manufacturer to be 
used for human beings for the purpose of diagnosis, pre-
vention, monitoring, treatment or alleviation of disease, 
must be considered a medical device (MD). Therefore, 
besides informing tube manufacturers about potential 
issues emerged during the validation process, the major 
safety and quality problems should also be reported to 
the pertinent regulatory national or supranational agency 
(i.e. FDA, EC or UK medicines and healthcare products 
regulatory).
The technical problems of blood tubes may also be 
investigated by means of objective approaches of risk 
analysis such as the Failure Mode and Effects Analysis 
(FMEA). This systematic technique was originally devel-
oped in the late 1950s to investigate problems emerging 
from military systems malfunctions. However, the FMEA 
approach may either be reliably used for identifying 
failure patterns of blood tubes, their causes and conse-
quences, and registering the information in specific FMEA 
worksheets [16]. Some previous experience in the field of 
preanalytical activities including blood collections have 
already been published [17].
Local clinical validation of blood collection 
tubes
The local (user) clinical validation of blood collection 
tubes should be intended to verify whether the new (i.e. 
“control”) blood collection tubes may be a source of bias 
in test results, as verified using local instrumentation and 
reagents. Therefore, the validation of new devices prior 
to routine introduction should entail statistical analysis 
of laboratory data obtained with the existing and locally 
validated blood collection tubes. The sample size should 
include between 20 and 100 (the higher the better) paired 
and sequential blood collections, using both the control 
and the comparative blood tube systems, by means of two 
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different venipunctures, preferably on the opposite arms, 
as recommended by the CLSI guidelines EP28-A3 to meet 
the minimum requirements for reliability and usefulness 
[18]. For the clinical validation, the EFLM WG-PRE sup-
ports the paired measurement of all laboratory param-
eters for which the comparative blood tubes are to be 
implemented.
For calculation of the maximum allowable deviation, 
the EFLM WG-PRE recommends comparing and analyz-
ing results obtained with the two different tube systems 
by Passing and Bablok regression (and/or Deming fit) 
and Bland and Altman plots, using values obtained with 
the control blood tubes as reference. When the regression 
is not acceptable and the mean percentage bias between 
the two blood tube systems is found to be greater than 
the previously defined desirable quality specifications 
for bias for each of the analyte tested, then the EFLM 
WG-PRE suggests that either (i) previous blood collection 
tube system is kept in use, or (ii) the laboratory imple-
ments new tubes, but modifies local reference ranges 
for parameters for which there is a clinically significant 
difference between old and new tubes. Quality specifi-
cations for validation experiments should be defined 
taking into consideration the Milan EFLM Strategic 
conference hierarchy [19]. The final evaluation should 
remain dependent upon the clinical decisions the results 
are used for, differences between health and disease and 
biological variation.
Conclusions
The validation of new laboratory equipment, instru-
mentation, methods and IVD devices by manufacturers 
and local users is a necessary part of clinical laboratory 
accreditation. Failure to comply with good manufactur-
ing or good laboratory practices may have adverse conse-
quences on operator and patient safety. Several lines of 
evidence now attest that the implementation of new blood 
collection devices, including blood tubes, may modify 
local practices and also influence the measured concen-
tration of the analytes. Indeed, the selection and acquisi-
tion of systems for blood collection should be considered 
a critical aspect for assuring quality, safety and efficiency 
of the preanalytical phase of laboratory diagnostics and, 
therefore, of total testing process. This issue is expected 
to become even more important as long as innovative 
molecular biomarkers make it through the translational 
process, and are introduced into routine clinical practice 
[20, 21], as this emerging arena is particularly vulnerable 
to preanalytical issues [22–24].
Although the CLSI document GP34-A is an useful tool 
for verifying tubes for venous and capillary blood drawing, 
the real impact of blood collection tubes on local quality 
and safety of testing is often overlooked, and laboratory 
professionals often fail to recognize the need to accurately 
assess the reliability of new devices or perform continu-
ous monitoring of ongoing performance [25]. Due to the 
fact that it is unfeasible for manufacturers to establish the 
impact of their devices on all instruments and reagents, 
the EFLM WG-PRE has drafted this consensus document 
with the aim of supporting laboratory professionals plan-
ning blood collection tube tenders and validating the 
devices before routine implementation. The laboratory 
professionals should also make sure that the tenders 
accurately and strictly define the responsibilities for vali-
dation experiments and the potential consequences in 
the case the validation outcome shows that tubes due not 
fulfill the expectations.
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